Presentation

Cardiac and vascular diseases continue to be the most common cause of death in the western world. Globally, more than 700.000 patients undergo coronary artery bypass surgery annually while about 600.000 patients have vascular surgery procedures performed. Medistim’s mission over the past three decades has been to serve patients, surgeons and health care providers with innovative and cost effective medical devices that measure blood flow and visualize atherosclerosis, and thereby help improve the quality and outcome of cardiac and vascular surgery.
Medistim has wholly owned subsidiaries with marketing and sales organizations in the USA, Germany, the United Kingdom, Spain, Denmark and Norway, in addition to a global distributor network representing the company in more than 50 countries in Asia, Europe, America and Africa. Sales revenues reached MNOK 363.7 MNOK (325.9 MNOK) in 2019, a growth of 11.6%. Medistim ASA is listed on the Oslo Stock Exchange and has its global head office in Oslo, Norway.